Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
Trump: U.S. has beaten Iran “militarily, economically, and in every other way”
Brazilian Icon Edmílson Takes Part in Global Football Initiative Showcasing Blockchain Sports
Azexo Announces Strategic Acquisition of IGAutoLike to Revolutionize Social Media Growth and Engagement Services
ForeclosureHub Launches New Platform for Discovering the Best Foreclosure Listings
Azbit Cryptocurrency Exchange Review: App Update and New Features
Qliktag Software Launches Qliktag.eu — A Dedicated EU-Hosted Platform for Digital Product Passport Compliance
The PayFi Supercycle Is Closer Than You Think — And Most of the Market Still Isn’t Positioned
Famoid Releases Landmark Social Media Engagement Report Spanning Two Million Creator Accounts
Kinnara clarifies position regarding Marina Bay City buyout discussions
Asprofin Bank Leads $10 Billion Sovereign Data Center Initiative Across Emerging Economies.
Home of Bestsellers Introduces Comprehensive Publishing Platform Empowering Authors Worldwide
Wyndham Member Month Returns: 5 Weeks of Deals
RCM Capitale Surpasses €480 Million in Assets Under Management, Signals Strategic Expansion into Emerging Asset Classes
What Is a Cloud Contact Center – And Why Modern Businesses Can’t Ignore It
Blockify: The All-in-One Security and Fraud Prevention Platform Protecting Over 30,000 Online Stores
A Cozy Farm-at-Sunset Bedtime Tale: “Clayton Gets A Bedtime Routine”
Aeternum and Da Nang Government Officials bring Unchained Summit to Da Nang
Tate vs McIntyre clash over Dubai as global expats explore emerging destinations
ThriveCart Acquires Automated Webinar Platform, Stealth Seminar
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.